Key result
Targeted IL-1β and IL-6 inhibition emerge as promising strategies to curb atherosclerotic inflammation.
Answers are grounded in this paper and cite their sources.
Targeted anti-inflammatory therapies, particularly selective blocking of the IL-6 trans-signaling pathway, hold promise for suppressing pathological inflammation in atherosclerosis.
Chronic inflammation is an independent risk factor of atherosclerosis and cardiovascular diseases (CVD). The initiator of this process is innate immune response through activation of pro-inflammatory cytokines — interleukin-1β (IL-1β) and interleukin-6 (IL-6). This review discusses current concepts of the role of inflammation in pathogenesis of atherosclerosis, focusing on IL-6 signaling pathways, its soluble receptor (sIL-6R) and glycoprotein 130 (gp130), as well as of C-reactive protein (CRP) as clinical biomarker of inflammation. Evidence on the role of inflammation obtained from various studies is reviewed. Special attention is paid to prospects of targeted anti-inflammatory therapy, including inhibition of IL-1β pathway, global inhibition of IL-6, and selective blocking of its trans-signaling pathway using soluble gp130 (sgp130). This would likely suppress pathological inflammation in atherosclerosis while preserving cytokine’s important protective functions and will become a key objective of future research.
No takes yet. Share an insight, caveat, or question.
Kaminnyi et al. (2025) conducted a review in Atherosclerosis and cardiovascular diseases. Targeted anti-inflammatory therapy (IL-1β and IL-6 inhibition) was evaluated. Targeted anti-inflammatory therapies, including IL-1β and IL-6 inhibition, are highlighted as promising strategies to suppress pathological inflammation in atherosclerosis.
Synapse has enriched 10 related papers. Consider them for comparative context: